Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With an IDH2 Mutation
Clinical trial NCT04203316 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04203316
- Sponsor
- Children's Oncology Group
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-08-14
- Primary completion
- 2025-09-30
- Enrollment
- 1
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.